As a finance expert, I often get asked whether mutual funds invest in CBD oil stocks. The short answer is yes, but the landscape is complex. The CBD industry sits at the intersection of healthcare, agriculture, and regulatory uncertainty, making it a unique but risky investment. In this article, I will explore mutual funds with exposure to CBD oil stocks, analyze their performance, and discuss the risks and opportunities involved.
Table of Contents
Understanding CBD Oil Stocks and the Market
CBD (cannabidiol) is a non-psychoactive compound derived from hemp or cannabis. Unlike THC, it does not produce a “high,” but it has gained traction in wellness and medical applications. The 2018 Farm Bill legalized hemp-derived CBD at the federal level, but FDA regulations remain unclear, creating volatility in the sector.
Key Players in the CBD Industry
Several publicly traded companies operate in the CBD space, including:
- Charlotte’s Web Holdings (CWBHF) – A leading producer of hemp-derived CBD products.
- Canopy Growth Corporation (CGC) – A cannabis giant with a strong CBD product line.
- Cronos Group (CRON) – Engages in CBD research and product development.
- GW Pharmaceuticals (acquired by Jazz Pharmaceuticals) – Developed Epidiolex, an FDA-approved CBD-based drug for epilepsy.
These stocks are often found in ETFs and mutual funds focusing on cannabis or alternative health sectors.
Mutual Funds with CBD Oil Stock Exposure
Most traditional mutual funds avoid pure-play CBD stocks due to regulatory risks. However, some sector-specific and thematic funds include them. Below are the main types of funds that may hold CBD-related stocks:
1. Cannabis-Focused Mutual Funds and ETFs
While true mutual funds in this space are rare, several ETFs provide exposure:
| Fund Name | Ticker | CBD Stock Holdings | Expense Ratio |
|---|---|---|---|
| ETFMG Alternative Harvest ETF | MJ | Canopy Growth, Cronos, Tilray | 0.75% |
| AdvisorShares Pure Cannabis ETF | YOLO | Charlotte’s Web, GW Pharma | 0.74% |
| Global X Cannabis ETF | POTX | Cronos, Canopy Growth | 0.50% |
These ETFs are the closest alternatives to mutual funds for CBD exposure.
2. Biotechnology and Healthcare Funds
Some biotech mutual funds hold GW Pharmaceuticals (now under Jazz Pharmaceuticals) due to its FDA-approved CBD drug. Examples include:
- Fidelity Select Biotechnology Portfolio (FBIOX) – Previously held GW Pharma.
- T. Rowe Price Health Sciences Fund (PRHSX) – Invests in innovative healthcare firms, including cannabinoid-based therapies.
3. Agricultural and Commodity Funds
Since hemp is an agricultural product, some agriculture-focused funds may include CBD-related stocks. However, direct exposure is limited.
Performance and Risk Analysis
Historical Returns
CBD stocks have been highly volatile. For example, the ETFMG Alternative Harvest ETF (MJ) had the following annual returns:
| Year | Return (%) |
|---|---|
| 2019 | -18.5 |
| 2020 | +12.3 |
| 2021 | -35.7 |
| 2022 | -62.4 |
This shows extreme fluctuations, typical of emerging industries with regulatory hurdles.
Risk Factors
- Regulatory Uncertainty – The FDA has not established clear CBD guidelines, leading to legal risks.
- Market Competition – The CBD market is crowded, with many small players struggling to turn a profit.
- Liquidity Risks – Many CBD stocks trade over-the-counter (OTC), making them less liquid.
Valuation Metrics
To assess whether CBD stocks are undervalued, I use the Price-to-Sales (P/S) ratio:
P/S = \frac{\text{Market Cap}}{\text{Annual Revenue}}For example, Charlotte’s Web Holdings had a market cap of $120M and revenue of $70M in 2022:
P/S = \frac{120}{70} \approx 1.71A P/S below 2 suggests potential undervaluation, but earnings matter more in the long run.
Should You Invest in CBD Oil Mutual Funds?
Pros:
- Growth Potential – The global CBD market could reach $47B by 2028 (Grand View Research).
- Diversification – ETFs spread risk across multiple stocks.
Cons:
- High Volatility – Regulatory changes can cause sharp price swings.
- Limited Pure-Play Options – Few mutual funds focus solely on CBD.
My Recommendation
If you seek CBD exposure, consider ETFs like MJ or YOLO instead of mutual funds. Alternatively, invest in biotech funds with indirect CBD holdings. Always allocate only a small portion (1-5%) of your portfolio to high-risk sectors.
Final Thoughts
While mutual funds with pure CBD oil stock exposure are scarce, ETFs and biotech funds offer alternatives. The CBD industry remains speculative, so due diligence is crucial. I suggest monitoring FDA regulations and company financials before investing.
